ClinicalTrials.gg
CompletedNCT01847404Updated Jul 13, 2017

Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions

A Phase 1 interventional study of Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one and Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two in Ulcers, Duodenal and Gastric, sponsored by GlaxoSmithKline. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Ulcer with a site in India — 2 open to participants now, 2 under way, 2 of them phase 3. Ulcer · India.

Enrollment
9th of 11
24 · median 70
Started
2013
with 2 others
Phase 1
3 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
2 of 11
GlaxoSmithKline

Among the 11 studies in Ulcer with a site in India, this one is the 9th largest by enrollment, is one of 3 that started in 2013, is one of 3 in phase 1, and was the 2nd registered.

Ulcer

359 studies on the registry are indexed under Ulcer; 61 are open to participants now.

Browse Ulcer studies →

Open to participants now

2 of the 11 studies in Ulcer with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 39 Ulcer studies recruiting now, 29 (74%) set no upper age limit and 4 (10%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ulcer with a site in India, or all of them as a file.
02

Study summary

An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study under fasting conditions. The treatments will be administered after an overnight fasting of at least 10 hours in each period. Fasting will continue for four hours post-dose, and then meals will be provided at specified intervals. Drinking water will not be permitted one hour before dosing and until one hour post-dose.

03

Conditions studied

  • Ulcers, Duodenal and Gastric

Browse trials for

Keywords

  • Fixed dose combination
  • Acetylsalicylic acid
  • Pantoprazole
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy human subjects within the age range of 18 to 45 years (both inclusive)
  • Non-smokers since at least six months
  • Willingness to provide written to participate in the study
  • Body-mass index () of >=18.5 kilogram per meter square (kg/m\^2) and \<=24.9 kg/m\^2, with body weight not less than 50 kg
  • Absence of significant disease or abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening
  • Normal 12-lead or one with abnormality considered to be clinically insignificant
  • Normal chest X-ray Posterior Anterior (PA) view
  • Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol.
  • Female Subject is eligible to participate if she is of non- (surgically sterile or for at least 1 year); or of child bearing potential practicing an acceptable method of while in the study and for 14 days after the end of the study, as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence
  • Male Subjects willing to use an approved form of birth control (a double barrier method like condom with spermicide or condom with diaphragm) while in the study and for 14 days after the end of the study, and agree not to donate sperm during this period.

Exclusion criteria

Exclusion criteria:

  • Personal / family history/ past history of allergy or to ASA or pantoprazole or related drugs
  • Any to anticoagulant therapy
  • History of sensitivity to heparin or heparin-induced thrombocytopenia
  • Past history of active gastric or duodenal ulcer or esophagitis
  • A history of cholecystectomy or biliary tract disease including increased liver function tests of known or unknown etiology
  • Subjects who have been diagnosed with Gilbert's syndrome (Elevated Liver Function Test (LFT)'s Serum Glutamate Oxaloacetate Transaminase/ Serum Glutamate Pyruvate Transaminase (/SGPT) + (total and direct))
  • Past history of anaphylaxis or angioedema
  • Any history of myopathy
  • Female subject not willing to use acceptable method of from the date of screening until 14 days after the end of the study
  • Male subject not willing to use acceptable method of contraception from the date of screening until 14 days after the end of the study
  • Any major illness in the past three months or any ongoing chronic medical illness e.g.congestive heart failure, hepatitis, pancreatitis etc.
  • Presence of any clinically significant abnormal values during screening e.g. significant abnormality of LFT, Renal (kidney) Function Test (RFT) etc.
  • Any cardiac, renal or liver impairment, any other organ or system impairment
  • History of seizure or psychiatric disorders
  • Presence of disease markers of human immuno deficiency virus () 1 and 2, and and C virus
  • History of significant alcohol consumption for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to check-in in each period and during the study [one drink is equal to one unit of alcohol [one glass wine, half pint beer, and one measure (one ounce) of spirit].
  • Presence of painful erythema, oedema, or ulceration in the oral cavity
  • Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period
  • Use of any recreational drug or a history of drug addiction
  • Participation in any clinical trial within the past 3 months
  • Inaccessibility of veins in left and right arm
  • Donation of blood [one unit or 330 millilitre (mL)] within 3 months prior to study check-in
  • History of use of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to study check-in or repeated use of drugs within the last four weeks
  • History of unusual diet, for whatever reason, e.g. low sodium diet, for 7 days prior to check-in for all the three periods
  • History of consumption of grapefruit-containing food or drinks within 7 days prior to the study check-in for all the three periods
  • Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 7 days prior to the study check-in for all the three periods
  • Difficulty in swallowing solids like tablets/capsules
  • Systolic blood pressure below 100 millimetres of mercury (mm Hg) and above 138 mm Hg, diastolic blood pressure below 60 mm Hg and above 90 mmHg
  • Heart rate below 60 beats/minute and above 100 beats/minute
  • Temperature below 96.0 degree Fahrenheit (F) and above 98.6 degree F
  • Female volunteers demonstrating a positive test for pregnancy during screening or currently breastfeeding
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Overall Study Arm

    All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet

    Drug: Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one · Drug: Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two · Drug: ASA 100 mg tablet · Drug: Pantoprazole 20 mg gastro-resistant tablet

Interventions

  • DrugTest 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one

    Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK

  • DrugTest 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two

    Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK

  • Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany

    Also known as: Aspirin Protect

  • Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany

    Also known as: Protium

06

What researchers measure

Primary outcomes

  1. Composite of pharmacokinetic (PK) parameters

    The bioavailability of two test products was compared with the reference products after determining the plasma PK parameters: Cmax (maximum measured plasma concentration), Tmax (time of Cmax), AUC0-t (area under the plasma concentration versus time curve from time zero to the last measurable concentration), AUC0-infinity (AUC from zero to infinity), t1/2 (time required for the plasma drug concentration to decrease by one half), Kel (terminal rate constant) and AUC_% Extrap_Obs (residual area in percentage determined by formula) for ASA and pantoprazole in relevant treatments.

    Time frame: During each period at pre-dose, 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 16 and 24 hrs post dose

Secondary outcomes

  1. Tolerability of combined ASA and pantoprazole in subjects during the study

    Tolerability of combined ASA and pantoprazole in subjects during the study assessed by adverse events, laboratory tests, vital signs and electrocardiogram (ECG).

    Time frame: Up to 16 days

07

Study locations

1 site
  • GSK Investigational Site
    Hyderabad, 500 013, India
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Jun 2013, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2013
First posted
May 6, 2013
StartActual
May 14, 2013
Primary completionActual
Jun 28, 2013
CompletionActual
Jun 28, 2013
Last update
Jul 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01847404
Lead sponsor
GlaxoSmithKline
Collaborators
Piramal Clinical Research (Hyderabad, India)
Responsible party
Sponsor
First posted
May 6, 2013
Start date
May 14, 2013
Primary completion
Jun 28, 2013
Completion
Jun 28, 2013
Last update
Jul 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Pantoprazole

Start the discussion